Adverse reactions of the digestive system caused by glucagon-like peptide-1 receptor agonists
- VernacularTitle:胰高血糖素样肽1受体激动剂相关的消化系统不良反应综述
- Author:
Chunxiao LU
1
;
Changfei LU
2
;
Huaqi ZHANG
2
;
Wenwen LIU
2
;
Xiaokang CUI
2
Author Information
1. Cheeloo College of Medicine，Shandong University，Jinan 250012，China
2. Shandong Center for Adverse Drug Reaction Monitoring，Jinan 250013，China
- Publication Type:Journal Article
- Keywords:
glucagon-like peptide-1 receptor agonists;
digestive system;
adverse reaction
- From:
China Pharmacy
2024;35(12):1539-1544
- CountryChina
- Language:Chinese
-
Abstract:
Glucagon-like peptide-1 receptor agonists （GLP-1RAs） have been widely used in diabetes and obese people in recent years， and they have also caused a series of adverse reactions， the most important of which is digestive system-related adverse reactions. The adverse reactions of the digestive system associated with GLP-1RAs involve the gastrointestinal， pancreatic， and biliary tracts； among them， nausea， vomiting， constipation， and diarrhea are the most common adverse reactions， which are the main reasons for drug withdrawal. The incidence of pancreatic and biliary system diseases is low， but there is no research evidence to exclude their association with GLP-1RAs. Tirzepatide appears on the market relatively late， and its safety still lacks sufficient real-world data. Medical staff should adopt active dietary guidance strategies for patients and strengthen medication education to help patients actively prevent and scientifically respond to adverse reactions in the digestive system.
